PMID- 15991274
OWN - NLM
STAT- MEDLINE
DCOM- 20050922
LR  - 20190430
IS  - 1007-9327 (Print)
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Linking)
VI  - 11
IP  - 25
DP  - 2005 Jul 7
TI  - Role of Helicobacter pylori eradication in aspirin or non-steroidal 
      anti-inflammatory drug users.
PG  - 3811-6
AB  - Helicobacter pylori (H pylori) infection and the use of non-steroidal 
      anti-inflammatory drugs (NSAIDs) including aspirin at any dosage and formulation 
      represent well-established risk factors for the development of uncomplicated and 
      complicated peptic ulcer disease accounting for the majority of such cases. 
      Although the interaction between H pylori and NSAID/aspirin use in the same 
      individuals was questioned in some epidemiological studies, it has now become 
      widely accepted that they are at least independent risk factors for peptic ulcer 
      disease. According to data from randomized intervention trials, naive NSAID users 
      certainly benefit from testing for H pylori infection and, if positive, H pylori 
      eradication therapy prior to the initiation of NSAID. A similar strategy is also 
      suggested for naive aspirin users, although the efficacy of such an approach has 
      not been evaluated yet. Strong data also support that chronic aspirin users with 
      a recent ulcer complication should be tested for H pylori infection and, if 
      positive, receive H pylori eradication therapy after ulcer healing, while they 
      appear to benefit from additional long-term therapy with a proton pump inhibitor 
      (PPI). A similar approach is often recommended to chronic aspirin users at a high 
      risk of ulcer complication. H pylori eradication alone does not efficiently 
      protect chronic NSAID users with a recent ulcer complication or those at a 
      high-risk, who certainly should be treated with long-term PPI therapy, but H 
      pylori eradication may be additionally offered even in this setting. In contrast, 
      testing for H pylori or PPI therapy is not recommended for chronic NSAID/aspirin 
      users with no ulcer complications or those at a low risk of complications.
FAU - Papatheodoridis, George-V
AU  - Papatheodoridis GV
AD  - Second Academic Department of Internal Medicine, Medical School of Athens 
      University, Hippokration General Hospital of Athens, 114 Vas. Sophias Ave., 
      Athens 115 27, Greece. gpapath@cc.uoa.gr
FAU - Archimandritis, Athanasios-J
AU  - Archimandritis AJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Gastrointestinal Diseases/*chemically induced/*prevention & control
MH  - Helicobacter Infections/*drug therapy
MH  - *Helicobacter pylori
MH  - Humans
PMC - PMC4504877
EDAT- 2005/07/02 09:00
MHDA- 2005/09/24 09:00
PMCR- 2005/07/07
CRDT- 2005/07/02 09:00
PHST- 2005/07/02 09:00 [pubmed]
PHST- 2005/09/24 09:00 [medline]
PHST- 2005/07/02 09:00 [entrez]
PHST- 2005/07/07 00:00 [pmc-release]
AID - 10.3748/wjg.v11.i25.3811 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2005 Jul 7;11(25):3811-6. doi: 10.3748/wjg.v11.i25.3811.